Klotho Neurosciences Files 8-K
Ticker: GRMLW · Form: 8-K · Filed: Oct 2, 2024 · CIK: 1907223
Sentiment: neutral
Topics: reporting, corporate-actions
TL;DR
Klotho Neurosciences filed an 8-K on 9/24, mostly standard disclosures.
AI Summary
Klotho Neurosciences, Inc. filed an 8-K on October 2, 2024, reporting an event on September 24, 2024. The company, formerly known as ANEW Medical, Inc. and Redwoods Acquisition Corp., is in the biological products sector. The filing details financial statements and exhibits, with no specific dollar amounts or new material events disclosed in the provided text.
Why It Matters
This filing indicates Klotho Neurosciences, Inc. is meeting its reporting obligations, providing a snapshot of its corporate activities and financial disclosures.
Risk Assessment
Risk Level: low — The filing appears to be a routine disclosure without immediate significant financial or operational changes.
Key Players & Entities
- Klotho Neurosciences, Inc. (company) — Registrant
- ANEW Medical, Inc. (company) — Former company name
- Redwoods Acquisition Corp. (company) — Former company name
- September 24, 2024 (date) — Date of earliest event reported
- October 2, 2024 (date) — Filing date
FAQ
What is the primary business of Klotho Neurosciences, Inc.?
Klotho Neurosciences, Inc. is in the BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) sector, SIC code 2836.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on September 24, 2024.
What were the previous names of Klotho Neurosciences, Inc.?
The company was formerly known as ANEW Medical, Inc. and Redwoods Acquisition Corp.
What is the filing date of this 8-K report?
This 8-K report was filed on October 2, 2024.
Where is Klotho Neurosciences, Inc. incorporated?
Klotho Neurosciences, Inc. is incorporated in Delaware.
Filing Stats: 573 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2024-10-02 12:30:33
Filing Documents
- ea0216422-8k_klotho.htm (8-K) — 28KB
- ea021642201ex99-1_klotho.htm (EX-99.1) — 11KB
- 0001213900-24-084456.txt ( ) — 260KB
- kltow-20240924.xsd (EX-101.SCH) — 3KB
- kltow-20240924_def.xml (EX-101.DEF) — 26KB
- kltow-20240924_lab.xml (EX-101.LAB) — 36KB
- kltow-20240924_pre.xml (EX-101.PRE) — 25KB
- ea0216422-8k_klotho_htm.xml (XML) — 6KB
01 Other Events
Item 8.01 Other Events. On September 24, 2024, the Company entered into a Scientific Advisory Board Agreement with Dr. Robert Langer (the "Agreement"). Pursuant to the Agreement, together with the other members of the Company's Scientific Advisory Board, Dr. Langer will advise the Company with respect to technical, scientific, fundraising and planning matters within his field of expertise, and in particular with respect to Company's neuroscience and needle-free injector programs. The Company's Scientific Advisory Board is a flexible, informal body that was created by the board of directors to provide the Company's management team with non-binding scientific advice. The members of the Scientific Advisory Board do not have the authority to vote on matters brought to the board of directors and may only attend a meeting of the board of directors if they are invited. Also, the members of the Scientific Advisory Board are not bound by fiduciary duties and are not entitled to indemnification. Also, on September 30, 2024, the Company issued a press release which announced the appointment of Dr. Lander to its Scientific Advisory Board. A copy of the press release is attached herein as Exhibit 99.1.
01 Financial
Item 9.01 Financial Exhibits Description 99.1 Press Release dated September 30, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: October 2, 2024 KLOTHO NEUROSCIENCES, INC. By: /s/ Joseph Sinkule Name: Joseph Sinkule Title: Chief Executive Officer 2